PatientsVille.com Logo

DISEASE PROGRESSION and ACIPHEX

PatientsVille

DISEASE PROGRESSION Symptoms and Causes

Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons.

There are many kinds of liver diseases:

  • Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C
  • Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis.
  • Liver cancer
  • Inherited diseases, such as hemochromatosis and Wilson disease

Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

Check out the latest treatments for DISEASE PROGRESSION

DISEASE PROGRESSION treatment research studies

ACIPHEX clinical trials, surveys and public health registries


Find Drug Side Effect reports



ACIPHEX Side Effects

Pain (30)
Headache (27)
Fatigue (24)
Nausea (24)
Dizziness (23)
Dyspnoea (22)
Chest Pain (22)
Diarrhoea (21)
Abdominal Pain Upper (19)
Pneumonia (18)
Cholecystitis Chronic (18)
Hypertension (17)
Oedema Peripheral (16)
Anxiety (16)
Cholelithiasis (16)
Myocardial Infarction (16)
Pruritus (15)
Pain In Extremity (14)
Depression (14)
Fall (13)
Loss Of Consciousness (13)
Dyspepsia (13)
Death (13)
Gallbladder Disorder (12)
Abdominal Pain (12)
Weight Decreased (12)
Asthenia (11)
Cerebrovascular Accident (11)
Feeling Abnormal (10)
Chronic Obstructive Pulmonary Disease (10)
Hypoaesthesia (10)
Rash (10)
Insomnia (10)
Pulmonary Embolism (10)
Paraesthesia (10)
Palpitations (10)
Injury (10)
Burning Sensation (9)
Muscle Spasms (9)
Chest Discomfort (9)
Arthralgia (9)
Deep Vein Thrombosis (8)
Emotional Distress (8)
Nephritis Interstitial (8)
Vomiting (8)
Cough (8)
Back Pain (8)
Cardiac Failure Congestive (8)
Condition Aggravated (8)
Coronary Artery Disease (8)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Have experienced polyneuropathy after taking aciphex this past year

I am a 28 year old female who was diagnosed 3 years ago with a hiatal hernia, 9 stomach ulcers and constant gastritis. They put me on aciphex. I have been on it ever since as it is the only thing that stops the pain. Just recently (within the

I have been taking aciphex for 7 days dont seem to be any different wonder if it takes a bit for it to work anyone else have this problem.

A flu epidemic at a boarding school would be a concern for the Centers for Disease Control true or false?

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

<b><span style=' padding: 0px; margin: 0px;'>Hi Can any1 tell me why this medicine (Betaserc) people use and if the disease is dangerous....plz tell me on urgent basis...any1 thnx</b>

<strong>I have very high blood pressure, was put on this drug approximately 5 weeks ago. I was on Coozar previous to this. I also take paracetamol x 1 bd, ceres x 1, venlafaxine x 1, omeprazole x 1, aspirin x 1, have Charcot Marie Tooth Disease

55 yo dx with osearthritis and degenative disc disease, prescribed Mobic 15 mg once a day on medication for past year with no problem.For the past 6weeks had gradual onset of facial and extremity edema , esophageal spasm and expir

After becoming very ill, suffering much pain, losing weight and having many sleepless nights i was finally diagnosed with hoshimotos disease, subsequently i have hypothyroidism. I am only talking 50 mg oroxine 3 times a week and 100 mg the other 2 d

As with any drug, you must weigh the benefits vs. the risks. Revlimid is an incredible drug, which controls my myeloplastic disease with deletion 5q

Can gestodene cause continous dizzyness or meniere's disease.

Centuximab has been diseastrous for me. My fingertips bleed and are infected as well as extremely painful to the touch. I have abdominal pains, constipation. What is worse, the CEA count has jumped and the disease has spread at an alarming rate.

DISEASE PROGRESSION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
Condition: Nonvariceal Upper Gastrointestinal Bleeding
Interventions: Drug: Intravenous Omeprazole;   Drug: Oral Rabeprazole
Outcome Measure: This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on bleeding control in patients with mild to moderate non-variceal UGIB.
2 Unknown  Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets
Conditions: Gastric Ulcer;   Duodenal Ulcer
Intervention: Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel
Outcome Measures: The primary end point is treatment success (ulcer healing rate).;   The secondary end point is incidence of ulcer bleeding within 12 weeks.
3 Recruiting A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Condition: Cancer
Interventions: Drug: Dabrafenib 150 mg twice a day (BID);   Drug: Rabeprazole 40 mg once daily (OD);   Drug: Rifampin 600 mg OD
Outcome Measures: PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment of Dabrafenib co administered with rabeprazole or rifampin;   PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   Ratio of metabolite to Dabrafenib;   Safety and tolerability assessment to measure vital signs;   Safety and tolerability assessment for 12-lead ECG;   Safety and tolerability assessment for laboratory tests;   Safety and tolerability assessment of dabrafenib in combination with rabeprazole or rifampin;   Concentrations of Rabeprazole in the presence of Dabrafenib;   Concentrations of Rifampin in the presence of Dabrafenib
4 Unknown  Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections
Condition: Helicobacter Pylori Infection
Interventions: Drug: RA5-RACM7;   Drug: RA3-RACM7;   Drug: RA7-RACM7
Outcome Measure: Eradication rate
5 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
6 Recruiting Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
Condition: Healthy
Interventions: Drug: palbociclib commercial free base;   Drug: famotidine;   Drug: rabeprazole;   Drug: antacid
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Apparent Oral Clearance (CL/F);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2)
7 Recruiting H2RA VS PPI for the Prevention of Ulcer Bleeding Associated With Low-dose Aspirin in Patients With Very High Ulcer Risk
Condition: Peptic Ulcer Bleeding
Interventions: Drug: Rabeprazole;   Drug: Famotidine
Outcome Measures: Recurrent ulcer bleeding;   Lower GI bleeding;   serious cardiothrombotic events
8 Recruiting Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Condition: Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Intervention: Drug: Rabeprazole Sodium
Outcome Measures: Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori;   Transition rate to secondary therapy for eradication of Helicobacter pylori
9 Unknown  Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10RAC+acetylcystein;   Drug: 10RAC+metronidazole
Outcome Measures: Re-eradication rate;   Influence of Participant's CYP2C19 genotype on re-eradication rate
10 Unknown  Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Conditions: Helicobacter Infections;   Gastritis;   Gastric Ulcer;   Duodenal Ulcer
Intervention: Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole
Outcome Measures: Which treatment yields the higher re-eradication rate of H. pylori infection;   Side effects
11 Recruiting The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
Condition: Reflux Esophagitis
Intervention: Drug: Newrabell® Tablet 10mg
Outcome Measures: Time to onset of first 1Day Heartburn free, Days;   Time to onset of first 2Days Heartburn free, Days;   1Day Heartburn free days, %;   Time in Daytime of first Heartburn free, Days;   Time in Nighttime of first Heartburn free, Days;   Weekly Heartburn Improvement Rate, %;   Average Daytime and Nighttime Heartburn Score Change at W4;   Average Daytime and Nighttime Heartburn Score Change at W8
12 Unknown  A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study
Condition: Chest Pain
Intervention: Drug: Rabeprazole 20mg twice daily
Outcome Measures: Symptoms assessment, quality of life.;   Compliance;   Adverse effects
13 Unknown  Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
Condition: Gastroesophageal Reflux Disease (GERD)
Interventions: Procedure: Transoral Incisionless Fundoplication;   Drug: Proton Pump Inhibitors; active control
Outcome Measures: GERD symptoms;   PPI usage;   Lower esophageal acid exposure;   Healed reflux esophagitis;   Rate of adverse events
14 Recruiting The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD
Condition: Gastroesophageal Reflux Disease
Intervention: Drug: Proton pump inhibitor (rabeprazole)
Outcome Measure: Symptom responders after PPI trials
15 Unknown  Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay
Condition: 30 Healthy People
Intervention: Drug: Clopidogrel and proton pump inhibitors
Outcome Measure: Comparison of the antiplatelet drug response apparently shown in TEG & Platelet mapping assay
16 Recruiting The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
Conditions: Non-erosive Reflux Disease;   Barrett's Esophagus
Interventions: Device: Ryodoraku;   Device: ANSWatch;   Device: UGI endoscopy;   Other: GerdQ;   Drug: PPI
Outcome Measures: gastroesophageal reflux disease questionnaire;   Upper gastrointestinal endoscopy
17 Recruiting Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: high dose dual therapy;   Drug: concomitant therapy
Outcome Measures: to compare the efficacy of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy;   to compare the adverse effects and patient adherence of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy
18 Unknown  Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
Condition: Gastroesophageal Reflux Disease
Intervention:
Outcome Measure: The incidence and severity of acid-related symptoms with GerdQ